Zdrowie i gospodarka · 09/01/2017

FDA Requests Public Comment on Generic Drug User Fee Amendments II Program Fees

The FDA is soliciting public input on its approach to administering generic drug program fees under the Generic Drug User Fee Amendments reauthorization (GDUFA II), with a focus on the initial inventory of approved abbreviated new drug application sponsors and application numbers for fiscal year 2018.